Tytuł pozycji:
LBA39 - IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
-
Tytuł:
-
LBA39 - IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
-
Autorzy:
-
Powles, T.
McDermott, D.F.
Rini, B.
Motzer, R.J.
Atkins, M.B.
Fong, L.
Joseph, R.W.
Pal, S.K.
Ravaud, A.
Bracarda, S.
Rodriguez, C. Suarez
Maio, M.
Gore, M.
Grünwald, V.
Staehler, M.
Qiu, J.
Thobhani, A.
Huseni, M.
Schiff, C.
Escudier, B.
-
Źródło:
-
In Annals of Oncology September 2017 28 Supplement 5:v624-v624
-